{"id":31185,"date":"2022-09-30T08:34:00","date_gmt":"2022-09-30T14:34:00","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=31185"},"modified":"2022-09-30T08:34:24","modified_gmt":"2022-09-30T14:34:24","slug":"brakke-viewpoint-september-30-2022","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-september-30-2022\/","title":{"rendered":"\u30d6\u30e9\u30c3\u30b1 \u30d3\u30e5\u30fc\u30dd\u30a4\u30f3\u30c8 2022 \u5e74 9 \u6708 30 \u65e5"},"content":{"rendered":"<p>\u3053\u306e\u30cb\u30e5\u30fc\u30b9\u30ec\u30bf\u30fc\u3092\u6bce\u9031\u8aad\u3093\u3067\u3044\u308b\u65b9\u306f\u3001\u79c1\u305f\u3061\u304c Zoetis \u793e\u306e Solensia (\u30d5\u30eb\u30cd\u30d9\u30c8\u30de\u30d6) \u306e\u7c73\u56fd\u5e02\u5834\u3078\u306e\u9032\u51fa\u72b6\u6cc1\u3092\u8ffd\u3063\u3066\u3044\u308b\u3053\u3068\u3092\u3054\u5b58\u77e5\u3067\u3057\u3087\u3046\u30022022 \u5e74 1 \u6708\u306b FDA \u306e\u627f\u8a8d\u3092\u5f97\u307e\u3057\u305f\u304c\u3001\u7c73\u56fd\u3067\u306f\u5148\u9031 Zoetis \u793e\u306b\u3088\u3063\u3066\u767a\u58f2\u3055\u308c\u305f\u3070\u304b\u308a\u3067\u3059\u3002<\/p>\n<p>\u30bd\u30ec\u30f3\u30b7\u30a2\u306f\u3001\u7c73\u56fd\u3067\u732b\u306e\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u6cbb\u7642\u5206\u91ce\u3092\u3064\u3044\u306b\u958b\u62d3\u3057\u307e\u3059\u3002\u3053\u306e\u88fd\u54c1\u306f\u3001\u6210\u719f\u3059\u308c\u3070\u5927\u30d2\u30c3\u30c8\uff08$1\u5104\u8d85\uff09\u306b\u306a\u308b\u3068\u4e88\u60f3\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u904e\u53bb20\u5e74\u4ee5\u4e0a\u306b\u308f\u305f\u308a\u3001\u72ac\u306eOA\u88fd\u54c1\u5e02\u5834\u306f\u52d5\u7269\u533b\u7642\u696d\u754c\u306e\u6210\u9577\u306e\u5927\u304d\u306a\u539f\u52d5\u529b\u3068\u306a\u3063\u3066\u304d\u305f\u305f\u3081\u3001\u732b\u306b\u5b89\u5168\u3067\u52b9\u679c\u7684\u306a\u521d\u306eOA\u6cbb\u7642\u85ac\u306e\u767a\u58f2\u306f\u3001\u5927\u304d\u306a\u8ffd\u52a0\u52b9\u679c\u3092\u3082\u305f\u3089\u3059\u3067\u3057\u3087\u3046\u3002\u73fe\u5728\u3001\u30be\u30a8\u30c6\u30a3\u30b9\u306f\u7363\u533b\u5b66\u306b\u304a\u3051\u308b\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u54c1\u306e\u72ec\u5360\u4f9b\u7d66\u306e\u7acb\u5834\u3092\u7dad\u6301\u3057\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u4eca\u5f8c12\u304b\u6708\u4ee5\u5185\u306b\u3001\u72ac\u306eOA\u6cbb\u7642\u85ac\u3068\u3057\u3066\u30be\u30a8\u30c6\u30a3\u30b9\u306eLibrela\uff08bedinvetmab\uff09\u304c\u7c73\u56fd\u3067\u767a\u58f2\u3055\u308c\u308b\u3068\u4e88\u60f3\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>2021\u5e74\u5f8c\u534a\u306b\u30d6\u30e9\u30c3\u30b1\u304c\u5b9f\u65bd\u3057\u305f\u5e02\u5834\u8abf\u67fb\u3067\u306f\u300190%\u4ee5\u4e0a\u306e\u7363\u533b\u5e2b\u304c\u3001\u51e6\u65b9\u85ac\u3067\u6cbb\u7642\u3055\u308c\u3066\u3044\u306a\u3044OA\u306e\u732b\u3092\u4e2d\u5fc3\u306b\u3001\u30bd\u30ec\u30f3\u30b7\u30a2\u3092\u4f7f\u7528\u3059\u308b\u53ef\u80fd\u6027\u304c\u9ad8\u3044\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002\u30be\u30a8\u30c6\u30a3\u30b9\u306f\u4eca\u5e74\u3001\u732b\u306eOA\u306b\u5bfe\u3059\u308b\u8a8d\u77e5\u5ea6\u3092\u9ad8\u3081\u308b\u305f\u3081\u306b\u61f8\u547d\u306b\u53d6\u308a\u7d44\u3093\u3067\u304d\u305f\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002\u73fe\u5728\u3001\u3053\u306e\u732b\u306e\u5e02\u5834\u306f\u5341\u5206\u306b\u30b5\u30fc\u30d3\u30b9\u304c\u63d0\u4f9b\u3055\u308c\u3066\u3044\u306a\u3044\u305f\u3081\u3001\u30bd\u30ec\u30f3\u30b7\u30a2\u306e\u767a\u58f2\u306f\u5927\u5e45\u306a\u5e02\u5834\u62e1\u5927\u3092\u3082\u305f\u3089\u3059\u3067\u3057\u3087\u3046\u3002\u3082\u3061\u308d\u3093\u3001\u72ac\u306eOA\u5e02\u5834\u306f\u3059\u3067\u306b\u304b\u306a\u308a\u6df7\u96d1\u3057\u3066\u3044\u308b\u305f\u3081\u3001\u30ea\u30d6\u30ec\u30e9\u306e\u767a\u58f2\u306e\u5f71\u97ff\u306f\u305d\u308c\u307b\u3069\u5927\u304d\u304f\u306a\u3044\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u304c\u3001\u305d\u308c\u3067\u3082\u91cd\u8981\u3067\u3059\u3002\u6642\u304c\u7d4c\u3066\u3070\u308f\u304b\u308b\u3067\u3057\u3087\u3046\u3002<\/p>\n<p><em>\u30b8\u30e0\u30fb\u30af\u30ed\u30de\u30f3<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>\u3053\u306e\u30cb\u30e5\u30fc\u30b9\u30ec\u30bf\u30fc\u3092\u6bce\u9031\u304a\u8aad\u307f\u3044\u305f\u3060\u3044\u3066\u3044\u308b\u65b9\u306f\u3001Zoetis\u793e\u306eSolensia\uff08\u30d5\u30eb\u30cd\u30d9\u30c8\u30de\u30d6\uff09\u306e\u7c73\u56fd\u5e02\u5834\u3078\u306e\u9032\u51fa\u72b6\u6cc1\u3092\u79c1\u305f\u3061\u304c\u8ffd\u3063\u3066\u304d\u305f\u3053\u3068\u3092\u3054\u5b58\u77e5\u3067\u3057\u3087\u3046\u3002FDA\u306e\u627f\u8a8d\u306f2022\u5e741\u6708\u3067\u3059\u304c\u3001Zoetis\u793e\u306f\u5148\u9031\u3001\u7c73\u56fd\u3067\u767a\u58f2\u3057\u305f\u3070\u304b\u308a\u3067\u3059\u3002Solensia\u306e\u767a\u58f2\u306b\u3088\u308a\u3001\u7c73\u56fd\u306b\u304a\u3051\u308b\u732b\u306e\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u6cbb\u7642\u85ac\u5e02\u5834\u304c\u3064\u3044\u306b\u958b\u62d3\u3055\u308c\u307e\u3059\u3002\u3053\u306e\u88fd\u54c1\u306f\u6210\u719f\u671f\u3092\u8fce\u3048\u308c\u3070\u3001\u30d6\u30ed\u30c3\u30af\u30d0\u30b9\u30bf\u30fc\uff081\u51044\u5343\u4e07\u30c8\u30f3\u8d85\uff09\u306b\u306a\u308b\u3068\u4e88\u60f3\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u72ac\u306eOA\uff08\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\uff09\u6cbb\u7642\u85ac\u5e02\u5834\u306f\u3001\u904e\u53bb20\u5e74\u4ee5\u4e0a\u306b\u308f\u305f\u308a\u52d5\u7269\u533b\u7642\u696d\u754c\u306e\u6210\u9577\u3092\u727d\u5f15\u3057\u3066\u304d\u305f\u305f\u3081\u3001\u732b\u306b\u3068\u3063\u3066\u5b89\u5168\u304b\u3064\u52b9\u679c\u7684\u306a\u521d\u306eOA\u6cbb\u7642\u85ac\u306e\u767a\u58f2\u306f\u3001\u5927\u304d\u306a\u4ed8\u52a0\u4fa1\u5024\u3092\u3082\u305f\u3089\u3059\u3067\u3057\u3087\u3046\u3002Zoetis\u793e\u306f\u73fe\u5728\u3001\u7363\u533b\u5b66\u5206\u91ce\u306b\u304a\u3051\u308b\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u54c1\u306e\u72ec\u5360\u4f9b\u7d66\u4f53\u5236\u3092\u7dad\u6301\u3057\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u4eca\u5f8c12\u30f6\u6708\u4ee5\u5185\u306b\u3001\u72ac\u306eOA\u6cbb\u7642\u85ac\u3068\u3057\u3066Zoetis\u793e\u306eLibrela\uff08\u30d9\u30b8\u30f3\u30d9\u30c8\u30de\u30d6\uff09\u304c\u7c73\u56fd\u3067\u767a\u58f2\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002 Brakke\u304c2021\u5e74\u5f8c\u534a\u306b\u5b9f\u65bd\u3057\u305f\u5e02\u5834\u8abf\u67fb\u306b\u3088\u308b\u3068\u3001\u7363\u533b\u5e2b\u306e90%\u4ee5\u4e0a\u304c\u30bd\u30ec\u30f3\u30b7\u30a2\u3092\u4f7f\u7528\u3059\u308b\u898b\u8fbc\u307f\u3067\u3001\u4e3b\u306b\u51e6\u65b9\u85ac\u3067\u6cbb\u7642\u3092\u53d7\u3051\u3066\u3044\u306a\u3044OA\u3092\u60a3\u3046\u732b\u3092\u5bfe\u8c61\u3068\u3057\u3066\u3044\u307e\u3059\u3002Zoetis\u793e\u306f\u4eca\u5e74\u3001\u732b\u306eOA\u306b\u5bfe\u3059\u308b\u8a8d\u77e5\u5ea6\u5411\u4e0a\u306b\u5c3d\u529b\u3057\u3066\u304d\u305f\u3068\u78ba\u4fe1\u3057\u3066\u3044\u307e\u3059\u3002\u73fe\u5728\u3001\u3053\u306e\u732b\u306e\u5e02\u5834\u306f\u5341\u5206\u306a\u30b5\u30fc\u30d3\u30b9\u304c\u63d0\u4f9b\u3067\u304d\u3066\u3044\u306a\u3044\u305f\u3081\u3001\u30bd\u30ec\u30f3\u30b7\u30a2\u306e\u767a\u58f2\u306f\u5e02\u5834\u3092\u5927\u5e45\u306b\u62e1\u5927\u3059\u308b\u3067\u3057\u3087\u3046\u3002\u3082\u3061\u308d\u3093\u3001\u72ac\u306eOA\u5e02\u5834\u306f\u975e\u5e38\u306b\u7af6\u4e89\u304c\u6fc0\u3057\u3044\u3067\u3059\u3002<\/p>\n<div class=\"view-full-post\"><a href=\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-september-30-2022\/\" class=\"view-full-post-btn\">\u5168\u6587\u3092\u898b\u308b<\/a><\/div>\n<p>;<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-31185","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-september-30-2022\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"If you read this newsletter each week, you know we\u2019ve been following the progress of Zoetis\u2019 Solensia (frunevetmab) into the US market.\u00a0 Although approved by the FDA in January 2022, it was just launched in the US by Zoetis this past week. Solensia opens finally opens the osteoarthritis treatment segment for cats in the US; the product is predicted to be a blockbuster (&gt;$100 million) when it matures.\u00a0 Since the market for OA products in dogs has been a major driver of growth in the animal health industry over the past 20+ years, launch of the first OA treatment safe and effective for cats will have a strong additional effect.\u00a0 Today Zoetis remains exclusively positioned to supply monoclonal antibody products in veterinary medicine.\u00a0 We also expect to see the launch of Zoetis\u2019 Librela (bedinvetmab) in the US to treat OA in dogs sometime in the next 12 months. Market research conducted by Brakke in late 2021 showed &gt;90% of veterinarians are likely to use Solensia, primarily in cats with OA that aren\u2019t being treated with a prescription medication.\u00a0 We believe that Zoetis has worked hard this year to create awareness of OA in cats.\u00a0 Today this feline market is substantially underserved, so the Solensia launch will cause significant market expansion.\u00a0 The OA market in dogs is of course quite crowdedView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-september-30-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-30T14:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-30T14:34:24+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint September 30, 2022\",\"datePublished\":\"2022-09-30T14:34:00+00:00\",\"dateModified\":\"2022-09-30T14:34:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/\"},\"wordCount\":241,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/\",\"url\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/#website\"},\"datePublished\":\"2022-09-30T14:34:00+00:00\",\"dateModified\":\"2022-09-30T14:34:24+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/ja\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint September 30, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/ja\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/ja\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/ja\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brakke Consulting\u304b\u3089\u306e\u30cb\u30e5\u30fc\u30b9","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-september-30-2022\/","og_locale":"ja_JP","og_type":"article","og_title":"News from Brakke Consulting","og_description":"If you read this newsletter each week, you know we\u2019ve been following the progress of Zoetis\u2019 Solensia (frunevetmab) into the US market.\u00a0 Although approved by the FDA in January 2022, it was just launched in the US by Zoetis this past week. Solensia opens finally opens the osteoarthritis treatment segment for cats in the US; the product is predicted to be a blockbuster (&gt;$100 million) when it matures.\u00a0 Since the market for OA products in dogs has been a major driver of growth in the animal health industry over the past 20+ years, launch of the first OA treatment safe and effective for cats will have a strong additional effect.\u00a0 Today Zoetis remains exclusively positioned to supply monoclonal antibody products in veterinary medicine.\u00a0 We also expect to see the launch of Zoetis\u2019 Librela (bedinvetmab) in the US to treat OA in dogs sometime in the next 12 months. Market research conducted by Brakke in late 2021 showed &gt;90% of veterinarians are likely to use Solensia, primarily in cats with OA that aren\u2019t being treated with a prescription medication.\u00a0 We believe that Zoetis has worked hard this year to create awareness of OA in cats.\u00a0 Today this feline market is substantially underserved, so the Solensia launch will cause significant market expansion.\u00a0 The OA market in dogs is of course quite crowdedView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-september-30-2022\/","og_site_name":"Brakke Consulting Website","article_published_time":"2022-09-30T14:34:00+00:00","article_modified_time":"2022-09-30T14:34:24+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"Amanda McDavid","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/ja\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint September 30, 2022","datePublished":"2022-09-30T14:34:00+00:00","dateModified":"2022-09-30T14:34:24+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/"},"wordCount":241,"articleSection":["Viewpoints"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/","url":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/","name":"Brakke Consulting\u304b\u3089\u306e\u30cb\u30e5\u30fc\u30b9","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/ja\/#website"},"datePublished":"2022-09-30T14:34:00+00:00","dateModified":"2022-09-30T14:34:24+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/ja\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/zh\/brakke-viewpoint-september-30-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/ja\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint September 30, 2022"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/ja\/#website","url":"https:\/\/brakkeconsulting.com\/ja\/","name":"Brakke Consulting\u306e\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/ja\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"\u30a2\u30de\u30f3\u30c0\u30fb\u30de\u30af\u30c7\u30a4\u30d3\u30c3\u30c9","url":"https:\/\/brakkeconsulting.com\/ja\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts\/31185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/comments?post=31185"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts\/31185\/revisions"}],"predecessor-version":[{"id":31186,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/posts\/31185\/revisions\/31186"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/media?parent=31185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/categories?post=31185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/ja\/wp-json\/wp\/v2\/tags?post=31185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}